共 50 条
- [1] Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutationGYNECOLOGIC ONCOLOGY, 2024, 190 : S67 - S67Schram, AlisonShapiro, GeoffreyThompson, JohnVandross, AndraeKummar, ShivaaniEl-Khoueiry, AnthonyLeDuke, KimFellous, MarcAlland, LeilaDumbrava, Ecaterina
- [2] First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutationJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Dumbrava, Ecaterina ElenaJohnson, Melissa LynneTolcher, Anthony W.Shapiro, GeoffreyThompson, John A.El-Khoueiry, Anthony B.Vandross, Andrae LavonKummar, ShivaaniParikh, Aparna RajMunster, Pamela N.Daly, ErikaDe Leon, LauraKhaddar, MeganLeDuke, KimberleyRobell, KimberlySheehan, Lisa IaconoSt Louis, MeagenWiebesiek, AmyAlland, LeilaSchram, Alison M.
- [3] PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development.CANCER RESEARCH, 2021, 81 (13)Dumble, MelissaXu, LizhongDominique, RomyrLiu, BinbinYang, HongMcBrayer, Mary-KateThomas, DafyddFahr, BruceLi, HongjuHuang, Kuo-SenRobell, KimberlyMulligan, ChrisRusso, BrandonPuzio-Kuter, AnnaDavis, ThomasBinh Vu
- [4] Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in DevelopmentACS MEDICINAL CHEMISTRY LETTERS, 2025, 16 (01): : 34 - 39Vu, Binh T.Dominique, RomyrFahr, Bruce J.Li, Hongju H.Fry, David C.Xu, LizhongYang, HongPuzio-Kuter, AnnaGood, AndrewLiu, BinbinHuang, Kuo-SenTanaka, NaokoDavis, Thomas W.Dumble, Melissa L.
- [5] GS-P-328, a brain-penetrant small molecule p53 Y220C reactivator for tumors harboring p53 Y220C mutationCANCER RESEARCH, 2024, 84 (06)Liu, MengGeng, KaijunLu, BiaoXia, YuanfengYang, Fanglong
- [6] Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2BLOOD, 2023, 142Carter, Bing Z.Mak, Po YeeKe, BaozhenNishida, YukiBoettcher, SteffenBedoy, AndreaOstermann, Lauren B.DiNardo, Courtney D.Puzio-Kuter, AnnaLevine, ArnoldAndreeff, Michael
- [7] Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53CANCER RESEARCH, 2024, 84 (07)Dumbrava, Ecaterina E.Iwamoto, Fabio M.Agulnik, MarkMilhem, MohammedTolcher, Anthony W.Chugh, RashmiDemeure, Michael J.Mita, AlainDemel, KurtDiamond, MarkMirakhur, BelooWilson, LaksmiOganesian, AramChan, DannaKeer, Harold N.Taylor, JasonSims, Martin J.Biondo, AndreaJueliger, SimoneSpira, Alexander
- [8] Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myelomaInvestigational New Drugs, 2020, 38 : 831 - 843W. Larry GluckMrinal M. GounderRichard FrankFerry EskensJean Yves BlayPhilippe A. CassierJean-Charles SoriaSant ChawlaVincent de WegerAndrew J. WagnerDavid SiegelFilip De VosErik RasmussenHaby A. Henary
- [9] Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myelomaINVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 831 - 843Gluck, W. LarryGounder, Mrinal M.Frank, RichardEskens, FerryBlay, Jean YvesCassier, Philippe A.Soria, Jean-CharlesChawla, Santde Weger, VincentWagner, Andrew J.Siegel, DavidDe Vos, FilipRasmussen, ErikHenary, Haby A.
- [10] Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute LeukemiaCLINICAL CANCER RESEARCH, 2022, 28 (05) : 870 - 881Stein, Eytan M.DeAngelo, Daniel J.Chromik, JoergChatterjee, ManikBauer, SebastianLin, Chia-ChiSuarez, Cristinade Vos, FilipSteeghs, NeeltjeCassier, Philippe A.Tai, DavidKiladjian, Jean-JacquesYamamoto, NoboruMous, RogierEsteve, JordiMinami, HironobuFerretti, StephaneGuerreiro, NelsonMeille, ChristopheRadhakrishnan, RajkumarPereira, BernardMariconti, LuisaHalilovic, EnsarFabre, ClaireCarpio, Cecilia